AOD-9604 stacks: what the evidence actually supports

Last updated 2026-07-25

Does stacking AOD-9604 with other peptides actually work?

Nobody knows, and that's the honest answer. There is no published human trial testing AOD-9604 combined with another peptide or drug for fat loss. Every stacking protocol you see online (AOD-9604 plus a GLP-1 agonist, plus CJC-1295, plus a SARM) is anecdote stacked on anecdote, not data stacked on data. That matters more here than with most peptides because AOD-9604's own solo record is weak. The compound came out of research into which fragment of human growth hormone drives fat metabolism without the growth-promoting and blood-sugar effects of full-length hGH ^[1]. The idea was clean: isolate the lipolytic region (amino acids 176-191), skip the rest, get fat loss without the diabetes risk. It's a genuinely elegant piece of peptide chemistry. The problem is that elegant mechanism never translated into a clear clinical win. A 2004 review covering AOD-9604's development as a metabolic agent describes it as a modified fragment of hGH designed to retain the fat-reducing activity of the parent hormone while dropping the growth-promoting and diabetogenic effects ^[1]. A 2006 review of obesity drugs in clinical development lists AOD-9604 among candidates that failed to show a body-weight effect clearly better than placebo in human obesity trials ^[2]. When the base compound's own placebo-controlled data is that thin, adding a second unproven agent on top doesn't create a combined benefit. It creates two unknowns instead of one.

What's the actual rationale behind combining AOD-9604 with GLP-1 drugs like semaglutide?

The logic people give is mechanism-splitting: GLP-1 drugs suppress appetite and slow gastric emptying, while AOD-9604 is supposed to act directly on fat cells to promote lipolysis, so combining them should hit two different pathways. It's a reasonable-sounding argument. It is not a tested one. Semaglutide and tirzepatide have real Phase 3 trial data behind them, published in flagship journals, with weight-loss numbers in the 12-21% range depending on the drug and dose. AOD-9604 has nothing comparable. The 2006 obesity-drug review that covered it alongside other candidates in development did not report a body-composition signal strong enough to carry it forward as a standalone obesity therapy ^[2]. If you're already on a GLP-1 drug and getting results, there's no trial showing AOD-9604 adds anything measurable on top of that. You'd be adding an unproven variable to a regimen that's already working through a well-documented mechanism. If you want to understand where AOD-9604 sits next to a drug with a cleaner trial record, the AOD-9604 vs tesamorelin comparison walks through a peptide that at least has FDA-approved indications behind it, which AOD-9604 does not.

Is stacking AOD-9604 with CJC-1295 or ipamorelin (GH secretagogues) a good idea?

This is probably the most common stack request, and it comes from a misunderstanding of what AOD-9604 is. CJC-1295 and ipamorelin work by stimulating your pituitary to release more of your own growth hormone. AOD-9604 is not a GH secretagogue. It's a synthetic fragment of the GH molecule itself, engineered specifically to strip out the GH-receptor-binding region so it does not act like growth hormone in the body ^[1]. Stacking a GH secretagogue with a fragment designed to not behave like GH is not obviously complementary. There's no published trial testing this combination for fat loss or anything else. If your actual goal is more GH activity for whatever reason (recovery, sleep, body composition), then a secretagogue plus real growth hormone research or a compound with human trial data (like tesamorelin, which is FDA-approved for a specific indication) is a more evidence-grounded lane than adding a compound whose own design goal was to avoid GH-like activity. Orthopedic and sports-medicine literature has started cataloging peptides used off-label for musculoskeletal repair and athletic performance, and reviews in this space explicitly note that many of these compounds, including growth-hormone-related peptides, lack controlled human safety and efficacy data outside of narrow approved uses ^{[3] [4]}. That caution applies to combinations even more than to single agents, because nobody has run the safety studies on the combination itself.

What does the human trial record on AOD-9604 alone actually show?

This is the part that gets buried in most peptide marketing, so it goes here in plain terms: AOD-9604 went through human obesity trials, and the weight-loss results did not separate convincingly from placebo. The compound was developed by an Australian biotech (Metabolic Pharmaceuticals) specifically as an anti-obesity candidate, built around the fat-metabolizing fragment of hGH ^{[1] [1]}. It reached Phase II human trials. But the 2006 review of obesity drugs in clinical development, covering the competitive landscape at the time, lists AOD-9604 among the candidates whose human trial outcomes did not clearly outperform placebo on the primary weight measures ^[2]. That's not a minor caveat. That's the trial failing to do the one thing an obesity drug needs to do in a controlled study: beat placebo by a margin that matters. There is no FDA-approved indication for AOD-9604. Check the FDA's own Drugs@FDA database, which lists every approved drug product in the US: AOD-9604 is not on it ^[5]. It never advanced to Phase III trials or to market as an obesity drug anywhere, as far as the published record shows. Anyone selling it as "clinically proven" for fat loss is overstating what two decades of published data actually contain. If you want the fuller trial-by-trial breakdown, the AOD-9604 peptide overview goes through the development history and what happened to the program after Phase II.

Does stacking change the doping-test detection picture?

This is worth knowing if you compete in any tested sport, because it's one of the few areas where there's actual published data specific to AOD-9604. A 2013 study in Drug Testing and Analysis tested whether AOD-9604 interferes with the World Anti-Doping Agency's hGH isoform immunoassay, the test WADA uses to detect growth hormone doping. The finding: AOD-9604 does not influence the WADA hGH isoform immunoassay ^[6]. In plain terms, taking AOD-9604 won't mask hGH use on that particular test, and it also won't trigger a false positive on it through that mechanism. But that doesn't mean it's undetectable or permitted; anti-doping labs have separate methods aimed specifically at small peptides. Separately, mass spectrometry methods built for detecting peptide drugs under 2 kDa in urine, using direct injection with liquid chromatography and ion mobility, have been developed specifically to catch compounds like AOD-9604 that fall below the size range older tests were built for ^[7]. Broader reviews of analytical approaches for detecting non-approved and emerging therapeutics in doping controls also cover peptide fragments like AOD-9604 as targets these newer screening methods are built to catch ^{[8] [9]}. If you're stacking AOD-9604 with anything else and you're a tested athlete, assume the whole stack is visible to modern peptide-screening methods, more than the GH-isoform test.

What about stacking AOD-9604 with SARMs or other bodybuilding compounds?

This combination shows up a lot in online forums, usually framed as a "cutting stack." The reasoning goes: SARMs preserve muscle in a calorie deficit, AOD-9604 supposedly targets fat directly, so together you get a leaner recomposition than either alone. There is no published human trial testing this combination. There is also no FDA approval for any SARM as a human drug; the FDA has issued warnings about SARMs being sold as dietary supplements, and none appear in the Drugs@FDA approved product database ^[5]. Stacking two unapproved, unproven compounds does not average out to one proven one. If anything, it multiplies the number of unknowns you're carrying, particularly around long-term safety, since sports-medicine reviews of peptide therapies used off-label for athletic performance and musculoskeletal recovery have specifically flagged the gap between how widely these compounds are used and how little controlled safety data exists for them ^{[3] [4]}. A therapeutic-peptides review covering orthopedic applications makes a similar point about the broader peptide category: promising mechanism and real lab-bench rationale don't substitute for controlled trial data for long-term use in humans ^[3].

Is it safe to combine AOD-9604 with other injectable peptides?

Nobody has published a safety study on AOD-9604 combined with another peptide, so "safe" isn't a word anyone can back with data here. What we can say is narrower: single-agent AOD-9604 has been through human trials without the severe adverse events associated with full-length growth hormone, which was the whole point of designing the fragment ^{[1] [1]}. That single-agent safety signal does not transfer to combinations. Drug interactions, immune responses to combined peptide exposure, and injection-site issues from multiple simultaneous products are all things a solo trial can't tell you about. Reviews of peptide therapies in sports medicine and orthopedics have called out this exact gap: widespread off-label combination use, essentially no controlled trials of the combinations themselves ^{[3] [4]}. If you're getting AOD-9604 through a legitimate route, sourcing quality and reconstitution practice matter even more once you're combining products, since dosing errors compound. The how to reconstitute AOD-9604 guide covers the mechanics of that step correctly, which is worth getting right regardless of what else is in the stack.

How is AOD-9604 actually sold, and does that affect stacking decisions?

In the US, AOD-9604 is not an FDA-approved drug, and it's not on either bulk drug substance list that allows compounding pharmacies to prepare it for human use under section 503A or 503B of the Food, Drug and Cosmetic Act. Those lists are the FDA's official inventories of substances compounders may legally use ^{[10] [11]}, and neither the current 503A bulks list ^[12] nor the 503B bulks list ^[13] includes AOD-9604 as of this writing. That has a direct practical effect on stacking. A licensed pharmacy compounding under 503A must use bulk substances that meet specific standards and appear on FDA's list, per 21 U.S.C. 353a ^[14]. Because AOD-9604 sits outside that framework in the US, most of what's sold domestically is labeled "research use only," not for human administration, regardless of what a seller's marketing implies. Making product claims about human fat loss for a research-labeled substance runs into FDA's own definition of "intended use" under 21 CFR 201.128, which looks at labeling, advertising, and how a product is marketed, more than what's printed on the vial ^[15]. When sourcing is already murky like this, adding a second or third unregulated peptide to the mix compounds the sourcing risk right along with the biological one. If you're going to research this compound at all, working through a provider-reviewed pathway matters more once you're combining substances, not less. AOD-9604 Co reviews providers on exactly this basis: verifiable sourcing, clear labeling, and no health claims that outrun the trial record. For anyone comparing where to source it, the best place to buy AOD-9604 breakdown and the AOD-9604 peptide for sale guide both cover what a legitimate listing should and shouldn't claim.

What would a more evidence-based alternative to stacking look like?

If your actual goal is body composition change with the best trial support available, the honest ranking looks different from what forum stacking threads suggest. GLP-1 receptor agonists (semaglutide, tirzepatide) have large randomized controlled trials published in major journals with double-digit percentage weight loss over roughly a year. Tesamorelin has FDA approval for a specific indication (HIV-associated lipodystrophy) with trial data behind that approval. AOD-9604, by comparison, has a 2004 mechanistic review describing its design rationale ^[1] and a 2006 obesity-drug landscape review noting it did not clearly beat placebo in human trials ^[2]. Those are two very different tiers of evidence, and no amount of stacking closes that gap, because stacking doesn't retroactively generate a trial that was never run. A cleaner path if you're set on researching AOD-9604 specifically: treat it as a single variable, at a defined dose, over a defined period, so you can actually tell whether anything changed. Stacking three unproven things at once means that if your weight or measurements shift, you have no idea which compound (if any) did it. That's not a research design, it's a guess with extra steps. For context on timing a single-agent protocol correctly, when to take AOD-9604 peptide covers the fasting-state timing rationale that shows up in the pharmacology literature, which is a more productive thing to optimize than adding a second unproven compound.

What should you actually do if you're considering a stack?

Start narrower than the forums suggest. If you're already on a GLP-1 drug and it's working, there's no trial evidence that adding AOD-9604 improves on that. If you're drawn to AOD-9604 specifically because you want to avoid GH-like side effects, adding a GH secretagogue on top works against that goal, not with it. The single most defensible move, evidence-wise, is to not stack at all until a controlled trial exists testing the combination you're interested in. That trial doesn't exist yet for any AOD-9604 combination as of this writing. If you do proceed anyway, keep the variable count as low as one, document dose and timing precisely, and go in knowing the base compound's own placebo-controlled record is the weak link, not the strongest argument for combining it with something else.

Frequently asked questions

Can you stack AOD-9604 with semaglutide or tirzepatide?

There's no published trial testing this combination. Semaglutide and tirzepatide have large randomized trials behind them; AOD-9604's own obesity trials did not clearly separate from placebo ^[3]. If a GLP-1 drug is already working for you, there's no evidence that adding AOD-9604 improves results, and you'd be adding an unproven variable to a regimen with real data.

Is AOD-9604 plus CJC-1295 a real fat-loss stack?

It's a popular combination online, but there's no human trial behind it. CJC-1295 raises your own GH output; AOD-9604 was specifically engineered to strip out GH-receptor-binding activity ^[1]. The rationale for combining a GH stimulator with a compound designed to avoid acting like GH is not well established in the literature.

Does AOD-9604 show up on a drug test if I'm stacking it with something else?

AOD-9604 does not interfere with the WADA hGH isoform immunoassay ^[7], but that doesn't mean it's undetectable. Mass spectrometry methods built for peptides under 2 kDa can detect AOD-9604 and similar compounds directly in urine ^[8], and it's covered by broader anti-doping detection reviews for emerging peptide therapeutics ^[9][10].

Did AOD-9604 ever pass human obesity trials?

AOD-9604 reached Phase II human trials as an obesity candidate, but a 2006 review of obesity drugs in clinical development lists it among compounds whose weight-loss results did not clearly beat placebo ^[3]. It has no FDA approval and does not appear in the Drugs@FDA database ^[6].

Is it legal to buy AOD-9604 in the US for stacking purposes?

AOD-9604 isn't on either FDA bulk drug substance list that permits compounding pharmacies to prepare it under section 503A or 503B ^[13][14], so it doesn't have a legal pathway as a compounded human drug in the US. Most domestic listings are labeled research-use-only, and marketing it for human fat loss can conflict with FDA's intended-use rules ^[16].

What's the actual mechanism AOD-9604 is supposed to work through?

AOD-9604 is a synthetic fragment covering roughly amino acids 176-191 of human growth hormone, the region researchers identified as responsible for hGH's fat-metabolizing (lipolytic) effect, built to exclude the growth-promoting and blood-sugar-raising regions of the full hormone ^[1][2].

Are there safety studies on combining AOD-9604 with SARMs?

No. There's no published human trial on this combination, and SARMs themselves have no FDA-approved human indication and don't appear in the Drugs@FDA database ^[6]. Sports-medicine reviews of off-label peptide and performance compounds specifically flag the gap between usage and controlled safety data ^[4][5].

Why do people stack AOD-9604 with other peptides if the trial data is weak?

Mostly because online protocols spread through forums and marketing rather than published trials, and the mechanism story (fat-targeting fragment plus appetite suppressant, or plus a GH booster) sounds logically complementary even without data testing it. The underlying AOD-9604 obesity trials didn't show a clear placebo-beating effect on their own ^[3].

How many peptides should you combine when researching AOD-9604?

If you're trying to learn anything from your own experience, one variable at a time is the only design that tells you anything. Stacking multiple unproven compounds means you can't attribute any change to a specific agent, which defeats the purpose of paying attention in the first place.

Does AOD-9604 cause the same side effects as full growth hormone when stacked?

AOD-9604 was designed specifically to exclude the growth-promoting and diabetogenic (blood-sugar-raising) regions of the hGH molecule ^[1][2], and single-agent human trials didn't report those classic hGH side effects. There's no published data on what happens when it's combined with other GH-pathway peptides, so that specific interaction is untested.

Is there an FDA-approved peptide that works like AOD-9604 but with better trial data?

Tesamorelin has FDA approval for HIV-associated lipodystrophy with trial data supporting that specific indication, unlike AOD-9604 which has no approved indication. See the AOD-9604 vs tesamorelin comparison for how their trial records actually differ.

Can stacking AOD-9604 with another peptide affect reconstitution or dosing accuracy?

Yes, practically speaking. Combining products increases the number of steps where dosing errors can happen, from mismatched concentrations to injection-site overlap. Getting the reconstitution and storage steps right for each individual peptide matters more, not less, once you're combining them; see how to reconstitute AOD-9604 for the correct procedure.

Sources

1. PubMed, AOD-9604 Metabolic: AOD-9604 is a modified hGH fragment engineered to retain fat-metabolizing activity while excluding the growth-promoting and diabetogenic regions of the hormone
2. PubMed, Obesity drugs in clinical development: 2006 review of obesity drug candidates lists AOD-9604 among compounds that did not clearly outperform placebo in human obesity trials
3. PubMed, Therapeutic Peptides in Orthopaedics: Reviews the gap between mechanistic promise and controlled human trial data for peptide therapies including growth-hormone-related compounds
4. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance: Flags the lack of controlled safety and efficacy data for many peptides used off-label in athletic performance and recovery contexts
5. FDA, Drugs@FDA approved drug products database: AOD-9604 and SARMs do not appear as FDA-approved drug products in the official database
6. PubMed, AOD-9604 does not influence the WADA hGH isoform immunoassay: 2013 study found AOD-9604 does not interfere with WADA's hGH isoform immunoassay
7. PubMed, Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, LC and ion mobility MS: Describes mass spectrometry methods developed to detect small peptides like AOD-9604 directly in urine
8. PubMed, Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls: Covers analytical methods used in anti-doping labs for detecting emerging peptide therapeutics
9. PubMed, Detecting peptidic drugs, drug candidates and analogs in sports doping: Reviews current and future detection methods for peptide drugs and analogs in sports doping controls
10. FDA, Bulk drug substances used in compounding under section 503A: Explains the FDA framework governing which bulk substances compounding pharmacies may legally use under 503A
11. FDA, Bulk drug substances nominated for use in compounding (current list): Lists substances nominated for the 503A/503B bulk drug substance evaluation process
12. eCFR, 21 CFR 216.23, the 503A Bulks List: AOD-9604 does not appear on the final 503A bulk drug substances list
13. eCFR, 21 CFR 216.24, the 503B Bulks List: AOD-9604 does not appear on the 503B bulk drug substances list
14. Cornell Law School, 21 U.S.C. 353a, pharmacy compounding: Sets the legal standard requiring 503A compounding pharmacies to use bulk substances that meet specified FDA standards
15. eCFR, 21 CFR 201.128, meaning of intended uses: Defines how labeling and marketing claims establish a product's intended use under FDA rules